The company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the ...

Boehringer Ingelheim halts Iclepertin trials after failure to show efficacy Boehringer Ingelheim stops research on Iclepertin ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...

Boehringer healthcare HCP Illustrative image Boehringer Ingelheim today announced top-line results from the Phase III CONNEX ...

Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...

Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...

R ood & Riddle Equine Hospital is hosting its annual Client Education Seminar, catering to professionals and enthusiasts in ...

Boehringer Ingelheim BioXcellence and Sutro Biopharma (STRO) announced that they successfully applied Sutro’s proprietary cell-free expression ...

Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on ...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were ...